Article

Multidisciplinary Management of Patients with Basal Cell Carcinoma

This publication highlights clinical perspectives on current treatment patterns in BCC, key findings from clinical trials, factors that influence clinical decision making, and opportunities for the development of novel therapies for this patient population.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!

Latest CME

View All
Addressing Unmet Needs in HER2+ Metastatic BTC
Video

Addressing Unmet Needs in HER2+ Metastatic BTC

Apr 18th 2025 - Apr 19th 2026

online-activity
View More
Community Oncology Connections™: Case Discussions in TNBC…Navigating the Latest Advances and Impact of Disparities in Care | North Carolina
Video

Community Oncology Connections™: Case Discussions in TNBC…Navigating the Latest Advances and Impact of Disparities in Care | North Carolina

Apr 17th 2025 - May 23rd 2025

online-activity
View More
Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Minnesota
Video

Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Minnesota

Apr 17th 2025 - May 23rd 2025

online-activity
View More
Related Content
Erika P. Hamilton, MD
December 5th 2022

Antibody-Drug Conjugates Expand HER2+ Breast Cancer Treatment Options

Peter Gibbs, MBBS, MD, FRACP, a medical oncologist at St Vincent’s Private Hospitals and a professor at the University of Melbourne in Australia
December 5th 2022

MRD Detection Emerges as a Catalyst for Advances in Colon Cancer

DetermaIO Assay Helps Inform Benefit With Single-Agent Immunotherapy in Advanced NSCLC
November 22nd 2022

DetermaIO Assay Helps Inform Benefit With Single-Agent Immunotherapy in Advanced NSCLC

Shaji Kumar, MD
September 1st 2022

Biomarker-Directed Therapy in Multiple Myeloma Signals the Future of the Field

Treating Patients with Gastric Cancer
August 25th 2022

Treating Patients with Gastric Cancer

Patients with recurrent, platinum-resistant ovarian cancer have limited effective treatment options available, but a class of targeted antibody-drug conjugates represent a promising development for this population.
July 20th 2022

ADCs Begin to Carve a Place in the Treatment Landscape for Ovarian Cancer